Scolaris Content Display Scolaris Content Display

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 1 Discontinuation ‐ overall at 6 months.
Figuras y tablas -
Analysis 1.1

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 1 Discontinuation ‐ overall at 6 months.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 2 Discontinuation ‐ overall at 12 months.
Figuras y tablas -
Analysis 1.2

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 2 Discontinuation ‐ overall at 12 months.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 3 Discontinuation ‐ amenorrhea.
Figuras y tablas -
Analysis 1.3

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 3 Discontinuation ‐ amenorrhea.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 4 Discontinuation ‐ menstrual changes.
Figuras y tablas -
Analysis 1.4

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 4 Discontinuation ‐ menstrual changes.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 5 Discontinuation ‐ non‐menstrual medical reasons.
Figuras y tablas -
Analysis 1.5

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 5 Discontinuation ‐ non‐menstrual medical reasons.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 6 Amenorrhea ‐ any time during 6‐month study.
Figuras y tablas -
Analysis 1.6

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 6 Amenorrhea ‐ any time during 6‐month study.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 7 Amenorrhea ‐ first reference period.
Figuras y tablas -
Analysis 1.7

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 7 Amenorrhea ‐ first reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 8 Infrequent bleeding ‐ first reference period.
Figuras y tablas -
Analysis 1.8

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 8 Infrequent bleeding ‐ first reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 9 Frequent bleeding ‐ first reference period.
Figuras y tablas -
Analysis 1.9

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 9 Frequent bleeding ‐ first reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 10 Prolonged bleeding ‐ first reference period.
Figuras y tablas -
Analysis 1.10

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 10 Prolonged bleeding ‐ first reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 11 Irregular bleeding ‐ first reference period.
Figuras y tablas -
Analysis 1.11

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 11 Irregular bleeding ‐ first reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 12 Normal bleeding ‐ first reference period.
Figuras y tablas -
Analysis 1.12

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 12 Normal bleeding ‐ first reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 13 Amenorrhea ‐ fourth reference period.
Figuras y tablas -
Analysis 1.13

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 13 Amenorrhea ‐ fourth reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 14 Infrequent bleeding ‐ fourth reference period.
Figuras y tablas -
Analysis 1.14

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 14 Infrequent bleeding ‐ fourth reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 15 Frequent bleeding ‐ fourth reference period.
Figuras y tablas -
Analysis 1.15

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 15 Frequent bleeding ‐ fourth reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 16 Prolonged bleeding ‐ fourth reference period.
Figuras y tablas -
Analysis 1.16

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 16 Prolonged bleeding ‐ fourth reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 17 Irregular bleeding ‐ fourth reference period.
Figuras y tablas -
Analysis 1.17

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 17 Irregular bleeding ‐ fourth reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 18 Normal bleeding ‐ fourth reference period.
Figuras y tablas -
Analysis 1.18

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 18 Normal bleeding ‐ fourth reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 19 Bleeding > 5 days ‐ first reference period.
Figuras y tablas -
Analysis 1.19

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 19 Bleeding > 5 days ‐ first reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 20 Bleeding > 5 days ‐ fourth reference period.
Figuras y tablas -
Analysis 1.20

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 20 Bleeding > 5 days ‐ fourth reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 21 Intermenstrual bleeding, moderate or severe ‐ first reference period.
Figuras y tablas -
Analysis 1.21

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 21 Intermenstrual bleeding, moderate or severe ‐ first reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 22 Intermenstrual bleeding, moderate or severe ‐ fourth reference period.
Figuras y tablas -
Analysis 1.22

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 22 Intermenstrual bleeding, moderate or severe ‐ fourth reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 23 Mean days of bleeding and spotting ‐ first reference period.
Figuras y tablas -
Analysis 1.23

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 23 Mean days of bleeding and spotting ‐ first reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 24 Mean days of bleeding and spotting ‐ second reference period.
Figuras y tablas -
Analysis 1.24

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 24 Mean days of bleeding and spotting ‐ second reference period.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 25 Weight gain (kg).
Figuras y tablas -
Analysis 1.25

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 25 Weight gain (kg).

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 26 Intention to continue method at study end.
Figuras y tablas -
Analysis 1.26

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 26 Intention to continue method at study end.

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 27 Experience with study method: very favorable or somewhat favorable.
Figuras y tablas -
Analysis 1.27

Comparison 1 DMPA 25 mg / E2C 5 mg versus DMPA 150 mg, Outcome 27 Experience with study method: very favorable or somewhat favorable.

Comparison 2 DHPA 150 mg / E2EN 10 mg versus DHPA 75 mg / E2EN 5 mg, Outcome 1 Bleeding or spotting days after third injection.
Figuras y tablas -
Analysis 2.1

Comparison 2 DHPA 150 mg / E2EN 10 mg versus DHPA 75 mg / E2EN 5 mg, Outcome 1 Bleeding or spotting days after third injection.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 1 Discontinuation ‐ overall.
Figuras y tablas -
Analysis 3.1

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 1 Discontinuation ‐ overall.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 2 Discontinuation ‐ pregnancy.
Figuras y tablas -
Analysis 3.2

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 2 Discontinuation ‐ pregnancy.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 3 Discontinuation ‐ amenorrhea.
Figuras y tablas -
Analysis 3.3

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 3 Discontinuation ‐ amenorrhea.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 4 Discontinuation ‐ heavy bleeding.
Figuras y tablas -
Analysis 3.4

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 4 Discontinuation ‐ heavy bleeding.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 5 Discontinuation ‐ prolonged bleeding.
Figuras y tablas -
Analysis 3.5

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 5 Discontinuation ‐ prolonged bleeding.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 6 Discontinuation ‐ irregular bleeding.
Figuras y tablas -
Analysis 3.6

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 6 Discontinuation ‐ irregular bleeding.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 7 Discontinuation ‐ spotting.
Figuras y tablas -
Analysis 3.7

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 7 Discontinuation ‐ spotting.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 8 Discontinuation ‐ other bleeding problems.
Figuras y tablas -
Analysis 3.8

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 8 Discontinuation ‐ other bleeding problems.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 9 Discontinuation ‐ any bleeding problem.
Figuras y tablas -
Analysis 3.9

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 9 Discontinuation ‐ any bleeding problem.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 10 Discontinuation ‐ other medical reason.
Figuras y tablas -
Analysis 3.10

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 10 Discontinuation ‐ other medical reason.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 11 Discontinuation ‐ other personal reason.
Figuras y tablas -
Analysis 3.11

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 11 Discontinuation ‐ other personal reason.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 12 Discontinuation ‐ late for or lost to follow‐up.
Figuras y tablas -
Analysis 3.12

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 12 Discontinuation ‐ late for or lost to follow‐up.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 13 Amenorrhea ‐ first reference period.
Figuras y tablas -
Analysis 3.13

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 13 Amenorrhea ‐ first reference period.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 14 Infrequent bleeding ‐ first reference period.
Figuras y tablas -
Analysis 3.14

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 14 Infrequent bleeding ‐ first reference period.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 15 Frequent bleeding ‐ first reference period.
Figuras y tablas -
Analysis 3.15

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 15 Frequent bleeding ‐ first reference period.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 16 Prolonged bleeding ‐ first reference period.
Figuras y tablas -
Analysis 3.16

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 16 Prolonged bleeding ‐ first reference period.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 17 Irregular bleeding ‐ first reference period.
Figuras y tablas -
Analysis 3.17

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 17 Irregular bleeding ‐ first reference period.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 18 Normal bleeding ‐ first reference period.
Figuras y tablas -
Analysis 3.18

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 18 Normal bleeding ‐ first reference period.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 19 Amenorrhea ‐ fourth reference period.
Figuras y tablas -
Analysis 3.19

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 19 Amenorrhea ‐ fourth reference period.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 20 Infrequent bleeding ‐ fourth reference period.
Figuras y tablas -
Analysis 3.20

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 20 Infrequent bleeding ‐ fourth reference period.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 21 Frequent bleeding ‐ fourth reference period.
Figuras y tablas -
Analysis 3.21

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 21 Frequent bleeding ‐ fourth reference period.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 22 Prolonged bleeding ‐ fourth reference period.
Figuras y tablas -
Analysis 3.22

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 22 Prolonged bleeding ‐ fourth reference period.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 23 Irregular bleeding ‐ fourth reference period.
Figuras y tablas -
Analysis 3.23

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 23 Irregular bleeding ‐ fourth reference period.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 24 Normal bleeding ‐ fourth reference period.
Figuras y tablas -
Analysis 3.24

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 24 Normal bleeding ‐ fourth reference period.

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 25 Weight at 12th month (kg).
Figuras y tablas -
Analysis 3.25

Comparison 3 NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg, Outcome 25 Weight at 12th month (kg).

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 1 Discontinuation ‐ overall.
Figuras y tablas -
Analysis 4.1

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 1 Discontinuation ‐ overall.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 2 Discontinuation ‐ pregnancy.
Figuras y tablas -
Analysis 4.2

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 2 Discontinuation ‐ pregnancy.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 3 Discontinuation ‐ amenorrhea.
Figuras y tablas -
Analysis 4.3

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 3 Discontinuation ‐ amenorrhea.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 4 Discontinuation ‐ heavy and prolonged bleeding.
Figuras y tablas -
Analysis 4.4

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 4 Discontinuation ‐ heavy and prolonged bleeding.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 5 Discontinuation ‐ irregular bleeding or spotting.
Figuras y tablas -
Analysis 4.5

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 5 Discontinuation ‐ irregular bleeding or spotting.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 6 Discontinuation ‐ other medical reasons.
Figuras y tablas -
Analysis 4.6

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 6 Discontinuation ‐ other medical reasons.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 7 Discontinuation ‐ other personal reasons.
Figuras y tablas -
Analysis 4.7

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 7 Discontinuation ‐ other personal reasons.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 8 Discontinuation ‐ late for, or lost to, follow up.
Figuras y tablas -
Analysis 4.8

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 8 Discontinuation ‐ late for, or lost to, follow up.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 9 Infrequent bleeding ‐ first reference period.
Figuras y tablas -
Analysis 4.9

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 9 Infrequent bleeding ‐ first reference period.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 10 Frequent bleeding ‐ first reference period.
Figuras y tablas -
Analysis 4.10

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 10 Frequent bleeding ‐ first reference period.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 11 Prolonged bleeding ‐ first reference period.
Figuras y tablas -
Analysis 4.11

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 11 Prolonged bleeding ‐ first reference period.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 12 Irregular bleeding ‐ first reference period.
Figuras y tablas -
Analysis 4.12

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 12 Irregular bleeding ‐ first reference period.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 13 Normal bleeding ‐ first reference period.
Figuras y tablas -
Analysis 4.13

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 13 Normal bleeding ‐ first reference period.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 14 Amenorrhea ‐ fourth reference period.
Figuras y tablas -
Analysis 4.14

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 14 Amenorrhea ‐ fourth reference period.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 15 Infrequent bleeding ‐ fourth reference period.
Figuras y tablas -
Analysis 4.15

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 15 Infrequent bleeding ‐ fourth reference period.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 16 Frequent bleeding ‐ fourth reference period.
Figuras y tablas -
Analysis 4.16

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 16 Frequent bleeding ‐ fourth reference period.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 17 Prolonged bleeding ‐ fourth reference period.
Figuras y tablas -
Analysis 4.17

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 17 Prolonged bleeding ‐ fourth reference period.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 18 Irregular bleeding ‐ fourth reference period.
Figuras y tablas -
Analysis 4.18

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 18 Irregular bleeding ‐ fourth reference period.

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 19 Normal bleeding ‐ fourth reference period.
Figuras y tablas -
Analysis 4.19

Comparison 4 NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg, Outcome 19 Normal bleeding ‐ fourth reference period.

Comparison 5 NET‐EN 50 mg / E2V 5 mg versus nonhormonal IUD, Outcome 1 Discontinuation ‐ bleeding.
Figuras y tablas -
Analysis 5.1

Comparison 5 NET‐EN 50 mg / E2V 5 mg versus nonhormonal IUD, Outcome 1 Discontinuation ‐ bleeding.

Comparison 5 NET‐EN 50 mg / E2V 5 mg versus nonhormonal IUD, Outcome 2 Pregnancy.
Figuras y tablas -
Analysis 5.2

Comparison 5 NET‐EN 50 mg / E2V 5 mg versus nonhormonal IUD, Outcome 2 Pregnancy.

Table 1. One‐year life‐table discontinuation rates: DMPA 25 mg / E2C 5 mg versus DMPA 150 mg

Study ID

Discontinue reason

Study group

Rate

SE

Cuong 1996

Overall

DMPA 25 mg / E2C 5 mg

25.7

2.5

DMPA 150 mg

27.0

2.6

Amenorrhea

DMPA 25 mg / E2C 5 mg

3.5

1.2

DMPA 150 mg

7.8

1.6

Prolonged bleeding

DMPA 25 mg / E2C 5 mg

1.2

0.7

DMPA 150 mg

2.1

0.9

Heavy and prolonged bleeding

DMPA 25 mg / E2C 5 mg

1.1

0.6

DMPA 150 mg

2.4

1.0

Irregular bleeding

DMPA 25 mg / E2C 5 mg

0.8

0.5

DMPA 150 mg

0.8

0.6

Spotting

DMPA 25 mg / E2C 5 mg

4.6

1.3

DMPA 150 mg

10.0

1.8

All bleeding problems

DMPA 25 mg / E2C 5 mg

7.4

1.6

DMPA 150 mg

14.9

2.1

Other medical reasons

DMPA 25 mg / E2C 5 mg

3.4

1.1

DMPA 150 mg

2.2

0.9

Other personal reasons

DMPA 25 mg / E2C 5 mg

10.0

1.8

DMPA 150 mg

3.0

1.1

Loss to follow up

DMPA 25 mg / E2C 5 mg

1.0

0.6

DMPA 150 mg

1.3

0.7

Figuras y tablas -
Table 1. One‐year life‐table discontinuation rates: DMPA 25 mg / E2C 5 mg versus DMPA 150 mg
Table 2. Life‐table discontinuation rate per 100 women‐years: NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg

Study ID

Discontinue reason

Study group

Rate

SE

Difference
in rates

(95% CI)

Hassan 1999

Overall

NET‐EN 50 mg / E2V 5 mg

38.0

1.5

‐0.9

‐‐‐

DMPA 25 mg / E2C 5 mg

38.9

2.9

Pregnancy

NET‐EN 50 mg / E2V 5 mg

0.4

0.2

0.2

‐‐‐

DMPA 25 mg / E2C 5 mg

0.2

0.1

Amenorrhea

NET‐EN 50 mg / E2V 5 mg

1.4

0.4

‐1.3

‐‐‐

DMPA 25 mg / E2C 5 mg

2.7

0.6

Heavy bleeding

NET‐EN 50 mg / E2V 5 mg

1.9

0.5

0.6

‐‐‐

DMPA 25 mg / E2C 5 mg

1.3

0.4

Prolonged bleeding

NET‐EN 50 mg / E2V 5 mg

2.0

0.5

0.5

‐‐‐

DMPA 25 mg / E2C 5 mg

1.5

0.4

Irregular bleeding

NET‐EN 50 mg / E2V 5 mg

2.4

0.5

0.8

‐‐‐

DMPA 25 mg / E2C 5 mg

1.6

0.4

Spotting

NET‐EN 50 mg / E2V 5 mg

1.0

0.3

0.6

‐‐‐

DMPA 25 mg / E2C 5 mg

0.4

0.2

All bleeding problems

NET‐EN 50 mg / E2V 5 mg

11.5

1.1

4.1

‐‐‐

DMPA 25 mg / E2C 5 mg

7.4

0.9

Other medical reasons

NET‐EN 50 mg / E2V 5 mg

4.7

0.7

‐3.1

‐‐‐

DMPA 25 mg / E2C 5 mg

7.8

3.8

All personal reasons

NET‐EN 50 mg / E2V 5 mg

12.8

1.1

0.4

‐‐‐

DMPA 25 mg / E2C 5 mg

12.4

1.1

Loss to follow‐up

NET‐EN 50 mg / E2V 5 mg

2.7

0.6

‐1.4

‐‐‐

DMPA 25 mg / E2C 5 mg

4.1

0.7

Mostafa 1994a

Overall

NET‐EN 50 mg / E2V 5 mg

59.2

4.1

5.2

‐‐‐

DMPA 25 mg / E2C 5 mg

54.0

5.0

Pregnancy

NET‐EN 50 mg / E2V 5 mg

0.7

0.7

0.7

‐‐‐

DMPA 25 mg / E2C 5 mg

0.0

0.0

Amenorrhea

NET‐EN 50 mg / E2V 5 mg

3.5

2.0

‐0.9

‐‐‐

DMPA 25 mg / E2C 5 mg

4.4

1.9

Heavy bleeding

NET‐EN 50 mg / E2V 5 mg

2.5

1.4

‐0.3

‐‐‐

DMPA 25 mg / E2C 5 mg

2.8

1.7

Prolonged bleeding

NET‐EN 50 mg / E2V 5 mg

0.0

0.0

‐1.5

‐‐‐

DMPA 25 mg / E2C 5 mg

1.5

1.0

Irregular bleeding

NET‐EN 50 mg / E2V 5 mg

6.3

2.6

4.5

‐‐‐

DMPA 25 mg / E2C 5 mg

1.8

1.3

Spotting

NET‐EN 50 mg / E2V 5 mg

0.8

0.8

0.8

‐‐‐

DMPA 25 mg / E2C 5 mg

0.0

0.0

All bleeding problems

NET‐EN 50 mg / E2V 5 mg

19.1

4.0

5.3

‐‐‐

DMPA 25 mg / E2C 5 mg

13.8

3.3

Other medical reasons

NET‐EN 50 mg / E2V 5 mg

15.9

3.7

‐0.5

‐‐‐

DMPA 25 mg / E2C 5 mg

16.4

6.4

All personal reasons

NET‐EN 50 mg / E2V 5 mg

24.4

4.3

‐0.4

‐‐‐

DMPA 25 mg / E2C 5 mg

24.8

4.1

Loss to follow up

NET‐EN 50 mg / E2V 5 mg

14.9

3.7

4.7

‐‐‐

DMPA 25 mg / E2C 5 mg

10.2

3.0

WHO 1988

Overall

NET‐EN 50 mg / E2V 5 mg

36.8

1.5

1.3

(‐2.6 to 5.4)

DMPA 25 mg / E2C 5 mg

35.5

1.4

Pregnancy

NET‐EN 50 mg / E2V 5 mg

0.2

0.1

0.2

(0.0 to 0.4)

DMPA 25 mg / E2C 5 mg

0

Amenorrhea

NET‐EN 50 mg / E2V 5 mg

1.6

0.4

‐0.5

(‐1.8 to 0.7)

DMPA 25 mg / E2C 5 mg

2.1

0.5

Bleeding irregularities

NET‐EN 50 mg / E2V 5 mg

7.5

0.9

1.2

(‐1.1 to 3.5)

DMPA 25 mg / E2C 5 mg

6.3

0.8

Figuras y tablas -
Table 2. Life‐table discontinuation rate per 100 women‐years: NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg
Comparison 1. DMPA 25 mg / E2C 5 mg versus DMPA 150 mg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Discontinuation ‐ overall at 6 months Show forest plot

1

100

Peto Odds Ratio (Peto, Fixed, 95% CI)

8.41 [1.82, 38.77]

2 Discontinuation ‐ overall at 12 months Show forest plot

1

360

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.24 [1.43, 3.50]

3 Discontinuation ‐ amenorrhea Show forest plot

1

100

Peto Odds Ratio (Peto, Fixed, 95% CI)

7.39 [0.15, 372.38]

4 Discontinuation ‐ menstrual changes Show forest plot

1

360

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.00 [0.71, 5.62]

5 Discontinuation ‐ non‐menstrual medical reasons Show forest plot

1

360

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.19 [0.80, 5.95]

6 Amenorrhea ‐ any time during 6‐month study Show forest plot

1

99

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.06 [0.03, 0.13]

7 Amenorrhea ‐ first reference period Show forest plot

2

841

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.23 [0.15, 0.34]

8 Infrequent bleeding ‐ first reference period Show forest plot

1

561

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.20 [0.13, 0.31]

9 Frequent bleeding ‐ first reference period Show forest plot

1

561

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.16 [0.48, 2.77]

10 Prolonged bleeding ‐ first reference period Show forest plot

1

561

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.34 [0.23, 0.50]

11 Irregular bleeding ‐ first reference period Show forest plot

1

561

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.88 [0.62, 1.25]

12 Normal bleeding ‐ first reference period Show forest plot

1

561

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.93 [3.48, 7.00]

13 Amenorrhea ‐ fourth reference period Show forest plot

2

609

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.10 [0.07, 0.14]

14 Infrequent bleeding ‐ fourth reference period Show forest plot

1

421

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.49 [0.28, 0.87]

15 Frequent bleeding ‐ fourth reference period Show forest plot

1

421

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.67 [0.37, 19.12]

16 Prolonged bleeding ‐ fourth reference period Show forest plot

1

421

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.60 [1.09, 11.89]

17 Irregular bleeding ‐ fourth reference period Show forest plot

1

421

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.75 [1.41, 5.36]

18 Normal bleeding ‐ fourth reference period Show forest plot

1

421

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.14 [4.19, 9.00]

19 Bleeding > 5 days ‐ first reference period Show forest plot

1

280

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.85 [1.07, 3.20]

20 Bleeding > 5 days ‐ fourth reference period Show forest plot

1

188

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.29 [2.59, 10.78]

21 Intermenstrual bleeding, moderate or severe ‐ first reference period Show forest plot

1

280

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.14 [0.03, 0.65]

22 Intermenstrual bleeding, moderate or severe ‐ fourth reference period Show forest plot

1

188

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.44 [0.14, 1.36]

23 Mean days of bleeding and spotting ‐ first reference period Show forest plot

1

43

Mean Difference (IV, Fixed, 95% CI)

‐6.0 [‐17.22, 5.22]

24 Mean days of bleeding and spotting ‐ second reference period Show forest plot

1

43

Mean Difference (IV, Fixed, 95% CI)

‐2.0 [‐8.29, 4.29]

25 Weight gain (kg) Show forest plot

1

442

Mean Difference (IV, Fixed, 95% CI)

‐0.20 [‐0.63, 0.23]

26 Intention to continue method at study end Show forest plot

1

100

Peto Odds Ratio (Peto, Fixed, 95% CI)

10.52 [4.71, 23.49]

27 Experience with study method: very favorable or somewhat favorable Show forest plot

1

306

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.48 [0.23, 1.02]

Figuras y tablas -
Comparison 1. DMPA 25 mg / E2C 5 mg versus DMPA 150 mg
Comparison 2. DHPA 150 mg / E2EN 10 mg versus DHPA 75 mg / E2EN 5 mg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Bleeding or spotting days after third injection Show forest plot

1

16

Mean Difference (IV, Fixed, 95% CI)

‐4.50 [‐9.01, 0.01]

Figuras y tablas -
Comparison 2. DHPA 150 mg / E2EN 10 mg versus DHPA 75 mg / E2EN 5 mg
Comparison 3. NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Discontinuation ‐ overall Show forest plot

3

6592

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.82 [0.74, 0.92]

2 Discontinuation ‐ pregnancy Show forest plot

2

6235

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.49 [0.76, 8.12]

3 Discontinuation ‐ amenorrhea Show forest plot

2

6235

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.32 [0.22, 0.44]

4 Discontinuation ‐ heavy bleeding Show forest plot

2

6235

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.79 [0.42, 1.45]

5 Discontinuation ‐ prolonged bleeding Show forest plot

2

6235

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.66 [0.48, 0.90]

6 Discontinuation ‐ irregular bleeding Show forest plot

2

6235

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.00 [0.66, 1.53]

7 Discontinuation ‐ spotting Show forest plot

2

6235

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.96 [0.52, 1.74]

8 Discontinuation ‐ other bleeding problems Show forest plot

2

6235

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.62 [0.37, 1.03]

9 Discontinuation ‐ any bleeding problem Show forest plot

1

357

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.88 [0.67, 5.28]

10 Discontinuation ‐ other medical reason Show forest plot

3

6592

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.07 [0.83, 1.37]

11 Discontinuation ‐ other personal reason Show forest plot

2

6235

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.09 [0.90, 1.33]

12 Discontinuation ‐ late for or lost to follow‐up Show forest plot

2

6235

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.99 [0.80, 1.22]

13 Amenorrhea ‐ first reference period Show forest plot

3

4070

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.69 [0.20, 2.37]

14 Infrequent bleeding ‐ first reference period Show forest plot

3

4073

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.45 [0.32, 0.64]

15 Frequent bleeding ‐ first reference period Show forest plot

3

4076

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.58 [1.27, 1.98]

16 Prolonged bleeding ‐ first reference period Show forest plot

3

4085

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.41 [0.32, 0.53]

17 Irregular bleeding ‐ first reference period Show forest plot

3

4072

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.69 [0.59, 0.81]

18 Normal bleeding ‐ first reference period Show forest plot

3

4095

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.68 [1.48, 1.90]

19 Amenorrhea ‐ fourth reference period Show forest plot

3

3100

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.91 [0.51, 1.62]

20 Infrequent bleeding ‐ fourth reference period Show forest plot

3

3106

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.73 [0.55, 0.97]

21 Frequent bleeding ‐ fourth reference period Show forest plot

3

3102

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.12 [0.79, 1.60]

22 Prolonged bleeding ‐ fourth reference period Show forest plot

3

3328

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.49 [0.35, 0.69]

23 Irregular bleeding ‐ fourth reference period Show forest plot

3

3102

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.83 [0.66, 1.05]

24 Normal bleeding ‐ fourth reference period Show forest plot

3

3095

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.39 [1.19, 1.62]

25 Weight at 12th month (kg) Show forest plot

1

134

Mean Difference (IV, Fixed, 95% CI)

1.10 [‐2.75, 4.95]

Figuras y tablas -
Comparison 3. NET‐EN 50 mg / E2V 5 mg versus DMPA 25 mg / E2C 5 mg
Comparison 4. NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Discontinuation ‐ overall Show forest plot

1

849

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.41 [1.07, 1.86]

2 Discontinuation ‐ pregnancy Show forest plot

1

849

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.30 [0.05, 1.75]

3 Discontinuation ‐ amenorrhea Show forest plot

1

849

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.54 [0.28, 1.05]

4 Discontinuation ‐ heavy and prolonged bleeding Show forest plot

1

849

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.57 [0.31, 1.07]

5 Discontinuation ‐ irregular bleeding or spotting Show forest plot

1

849

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.97 [0.56, 1.67]

6 Discontinuation ‐ other medical reasons Show forest plot

1

849

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.24 [1.23, 4.07]

7 Discontinuation ‐ other personal reasons Show forest plot

1

849

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.93 [1.26, 2.97]

8 Discontinuation ‐ late for, or lost to, follow up Show forest plot

1

849

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.76 [1.05, 2.95]

9 Infrequent bleeding ‐ first reference period Show forest plot

1

430

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.33 [0.20, 0.55]

10 Frequent bleeding ‐ first reference period Show forest plot

1

430

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.66 [0.35, 1.26]

11 Prolonged bleeding ‐ first reference period Show forest plot

1

430

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.02 [0.31, 3.41]

12 Irregular bleeding ‐ first reference period Show forest plot

1

430

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.81 [0.54, 1.21]

13 Normal bleeding ‐ first reference period Show forest plot

1

430

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.17 [2.14, 4.71]

14 Amenorrhea ‐ fourth reference period Show forest plot

1

430

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.36 [0.16, 0.82]

15 Infrequent bleeding ‐ fourth reference period Show forest plot

1

430

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.60 [0.40, 0.89]

16 Frequent bleeding ‐ fourth reference period Show forest plot

1

430

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.62 [0.17, 2.34]

17 Prolonged bleeding ‐ fourth reference period Show forest plot

1

430

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.82 [0.14, 4.81]

18 Irregular bleeding ‐ fourth reference period Show forest plot

1

430

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.80 [1.56, 5.01]

19 Normal bleeding ‐ fourth reference period Show forest plot

1

430

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.59 [1.08, 2.34]

Figuras y tablas -
Comparison 4. NET‐EN 50 mg / E2V 5 mg versus NET‐EN 200 mg
Comparison 5. NET‐EN 50 mg / E2V 5 mg versus nonhormonal IUD

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Discontinuation ‐ bleeding Show forest plot

1

148

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.67 [2.08, 21.41]

2 Pregnancy Show forest plot

1

148

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.22 [0.02, 2.47]

Figuras y tablas -
Comparison 5. NET‐EN 50 mg / E2V 5 mg versus nonhormonal IUD